Accenture Invests in QuantHealth to Accelerate Use of AI-powered Clinical Trial Simulations to Drive Cost-Effective Drug Development
08 Janeiro 2024 - 9:59AM
Business Wire
Accenture (NYSE: ACN) announced it has made a strategic
investment, through Accenture Ventures, in QuantHealth, an
AI-powered clinical trial design company that simulates clinical
trials in the cloud, allowing pharmaceutical and biotech companies
to more quickly and cost-effectively develop treatments for
patients.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240108611264/en/
Accenture announced it has made a
strategic investment, through Accenture Ventures, in QuantHealth,
an AI-powered clinical trial design company that simulates clinical
trials in the cloud, allowing pharmaceutical and biotech companies
to more quickly and cost-effectively develop treatments for
patients. (Photo: Business Wire)
With proprietary AI technology trained on a massive dataset of
350 million patients, large biomedical knowledge-graphs, and
clinical trial data, QuantHealth’s simulation platform can predict
trial outcomes with significant accuracy. It can test thousands of
protocol variations and discover the optimal trial design for
success, helping research and development (R&D) teams more
accurately and rapidly predict clinical trial results and decide
whether a trial should proceed, how to optimize cohorts, whether
drugs can be repurposed, and other crucial factors.
“QuantHealth’s clinical trial simulation platform can fast-track
clinical trials and help pharmaceutical and biotech companies bring
life-saving treatments to patients” said Tom Lounibos, global lead
of Accenture Ventures. “By accelerating and enhancing global drug
discovery efforts, we’ll aim to work alongside QuantHealth, our
clients and ecosystem partners to expand medicine and treatment
options and find new opportunities to bolster patient care.”
Clinical trials can cost billions of dollars to execute, with
only 10% of drugs making it to market. Each year, trial failures
collectively cost companies billions of dollars in losses,
representing an estimated 20% of the global pharmaceutical R&D
budget. Drug population and drug protocol fit account for nearly
75% of these failures. By simulating trials at scale, QuantHealth’s
platform can lower risks, expedite, and optimize drug development.
QuantHealth is already working with several global pharmaceutical
companies to use its product in clinical trial design and
development.
Petra Jantzer, Ph.D., global lead of the Accenture Life Sciences
business, said, "Through our investment in QuantHealth, we are
further solidifying our commitment to utilizing advanced
technologies to bring revolutionary change in the pharmaceutical
industry. With the aid of AI-designed clinical trial simulations,
we can reduce the cost and duration of creating effective
medications, which is crucial for improving health outcomes."
“Clinical trials are a costly and uncertain process, where the
R&D cost of a new drug can be upwards of $1 billion,” said Orr
Inbar, co-founder and CEO of QuantHealth. “QuantHealth has created
a solution that uses AI to transform how pharmaceutical companies
approach their clinical trials. We’re able to seamlessly integrate
data and cloud technology into the clinical trial process, not only
saving time and money for pharmaceutical companies, but also
increasing the chance of success in drug development. Accenture’s
long-standing experience in this industry and leadership in data
and AI will help us continue to scale our platform globally.”
QuantHealth is the latest company to join Accenture Ventures’
Project Spotlight, an engagement and investment program focused on
working with companies that create or apply disruptive enterprise
technologies. Project Spotlight offers extensive access to
Accenture’s domain expertise and its enterprise clients, helping
startups harness creativity and deliver on the promise of their
technology. Additional digital simulation companies in Project
Spotlight include Virtonomy and Ocean Genomics.
Terms of the investment were not disclosed.
About Accenture
Accenture is a leading global professional services company that
helps the world’s leading businesses, governments and other
organizations build their digital core, optimize their operations,
accelerate revenue growth and enhance citizen services—creating
tangible value at speed and scale. We are a talent- and
innovation-led company with approximately 743,000 people serving
clients in more than 120 countries. Technology is at the core of
change today, and we are one of the world’s leaders in helping
drive that change, with strong ecosystem relationships. We combine
our strength in technology and leadership in cloud, data and AI
with unmatched industry experience, functional expertise and global
delivery capability. We are uniquely able to deliver tangible
outcomes because of our broad range of services, solutions and
assets across Strategy & Consulting, Technology, Operations,
Industry X and Song. These capabilities, together with our culture
of shared success and commitment to creating 360° value, enable us
to help our clients reinvent and build trusted, lasting
relationships. We measure our success by the 360° value we create
for our clients, each other, our shareholders, partners and
communities. Visit us at www.accenture.com.
About QuantHealth
90% of drugs fail the clinical stage, representing a direct $50B
annual waste to pharma companies. To address this challenge at its
core, QuantHealth's Clinical-Simulator predicts how each patient in
a clinical trial will respond to treatment, allowing trial design
teams to predict how an entire clinical trial will play out, and
optimize trial design. Based on its novel AI engine and a vast
dataset of 350m patients and over 700K therapeutics, QuantHealth's
simulator can predict clinical trial results with 86% accuracy,
allowing users to answer mission critical questions such as cohort
optimization, indication selection, in-licensing asset evaluation,
and more. QuantHealth was founded by healthcare experts who led
commercial, product, and data science at various leading companies
in the US and Israel. QuantHealth is backed by expert Life-Science
investors in the US, Europe and Israel, and is supported by an
advisory board of physicians and scientists from leading academic
institutions.
Copyright © 2024 Accenture. All rights reserved. Accenture and
its logo are registered trademarks of Accenture.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240108611264/en/
Marchell Gillis Accenture +1 678 657 7515
marchell.gillis@accenture.com
Accenture (NYSE:ACN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Accenture (NYSE:ACN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024